Ozempic, Inhalers, In The Crosshairs As FTC Goes After Hundreds More ‘Junk Patents’

Teva, GSK, Boehringer, And Novartis Among Companies Targeted In Fresh Wave

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.